Circulating Levels of Interleukin 1-Receptor Antagonist and Risk of Cardiovascular Disease: Meta-Analysis of Six Population-Based Cohorts

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 37, Issue 6, 2017, Pages 1222-1227

  Herder, Christian ^a   De Las Heras Gala, Tonia ^b   Carstensen Kirberg, Maren ^c   Huth, Cornelia ^d   Zierer, Astrid ^c   Wahl, Simone ^e   Sudduth Klinger, Julie ^f   Kuulasmaa, Kari ^g   Peretz, David ^a   Ligthart, Symen ^h   Bongaerts, Brenda W C ^f   Dehghan, Abbas ⁱ   Arfan Ikram, M ^j   Jula, Antti ^k   Kee, Frank ^l   Pietilä, Arto ^d   Saarela, Olli ^c   Zeller, Tanja ^c   Blankenberg, Stefan ^c   Meisinger, Christa ^c   Peters, Annette ^m   Roden, Michael ⁿ   Salomaa, Veikko ^o   Koenig, Wolfgang ^c   Thorand, Barbara ^a   more..

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^e Tethys Bioscience   (United States)

^f NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h IMPERIAL COLLEGE LONDON   (United Kingdom)

ⁱ QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^j QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^k UNIVERSITY OF TORONTO   (Canada)

^l UNIVERSITY HEART CENTER HAMBURG   (Germany)

^m UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

ⁿ TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^o UNIVERSITY HOSPITAL ULM   (Germany)

more..

Author keywords

biomarker; cardiovascular disease; cohort study; inflammation; interleukin 1 receptor antagonist; meta analysis

Indexed keywords

C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; MYELOPEROXIDASE; BIOLOGICAL MARKER; IL1RN PROTEIN, HUMAN;

ANTHROPOMETRIC PARAMETERS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; EFFECT SIZE; FOLLOW UP; HAZARD RATIO; HUMAN; INCIDENCE; LIFESTYLE; META ANALYSIS; METABOLIC PARAMETERS; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTEMATIC REVIEW; BLOOD; CARDIOVASCULAR DISEASES; ODDS RATIO; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR;

BIOMARKERS; CARDIOVASCULAR DISEASES; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; ODDS RATIO; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 85018831667     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.117.309307     Document Type: Article

References (34)

1. Hansson GK, Hermansson A, The immune system in atherosclerosis. Nat Immunol 2011 12 204 212. doi: 10.1038/ni.2001.
2. Dinarello CA, Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009 27 519 550. doi: 10.1146/annurev.immunol.021908.132612.
3. Ridker PM, From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection. Circ Res 2016 118 145 156. doi: 10.1161/CIRCRESAHA.115.306656.
4. Herder C, Dalmas E, Böni-Schnetzler M, Donath MY, The IL-1 pathway in type 2 diabetes and cardiovascular complications. Trends Endocrinol Metab 2015 26 551 563. doi: 10.1016/j.tem.2015.08.001.
5. Ridker PM, Thuren T, Zalewski A, Libby P, Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 2011 162 597 605. doi: 10.1016/j.ahj.2011.06.012.
6. Arend WP, Gabay C, Physiologic role of interleukin-1 receptor antagonist. Arthritis Res 2000 2 245 248. doi: 10.1186/ar94.
7. Dinarello CA, Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011 117 3720 3732. doi: 10.1182/blood-2010-07-273417.
8. Herder C, Nuotio ML, Shah S, Genetic determinants of circulating interleukin-1 receptor antagonist levels and their association with glycemic traits. Diabetes 2014 63 4343 4359. doi: 10.2337/db14-0731.
9. Meier CA, Bobbioni E, Gabay C, Assimacopoulos-Jeannet F, Golay A, Dayer JM, IL-1 receptor antagonist serum levels are increased in human obesity: a possible link to the resistance to leptin? J Clin Endocrinol Metab 2002 87 1184 1188. doi: 10.1210/jcem.87.3.8351.
10. Herder C, Brunner EJ, Rathmann W, Strassburger K, Tabák AG, Schloot NC, Witte DR, Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes: the Whitehall II study. Diabetes Care 2009 32 421 423. doi: 10.2337/dc08-1161.
11. Grossmann V, Schmitt VH, Zeller T, Profile of the Immune and Inflammatory Response in Individuals With Prediabetes and Type 2 Diabetes. Diabetes Care 2015 38 1356 1364. doi: 10.2337/dc14-3008.
12. Herder C, Færch K, Carstensen-Kirberg M, Lowe GD, Haapakoski R, Witte DR, Brunner EJ, Roden M, Tabák AG, Kivimäki M, Vistisen D, Biomarkers of subclinical inflammation and increases in glycaemia, insulin resistance and beta-cell function in non-diabetic individuals: the Whitehall II study. Eur J Endocrinol 2016 175 367 377. doi: 10.1530/EJE-16-0528.
13. Blankenberg S, Zeller T, Saarela O, Havulinna AS, Kee F, Tunstall-Pedoe H, Kuulasmaa K, Yarnell J, Schnabel RB, Wild PS, Münzel TF, Lackner KJ, Tiret L, Evans A, Salomaa V, MORGAM Project Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation 2010 121 2388 2397. doi: 10.1161/CIRCULATIONAHA.109.901413.
14. Ligthart S, Sedaghat S, Ikram MA, Hofman A, Franco OH, Dehghan A, EN-RAGE: a novel inflammatory marker for incident coronary heart disease. Arterioscler Thromb Vasc Biol 2014 34 2695 2699. doi: 10.1161/ATVBAHA.114.304306.
15. Patti G, Di Sciascio G, D'Ambrosio A, Dicuonzo G, Abbate A, Dobrina A, Prognostic value of interleukin-1 receptor antagonist in patients undergoing percutaneous coronary intervention. Am J Cardiol 2002 89 372 376
16. Looker HC, Colombo M, Agakov F, SUMMIT Investigators Protein biomarkers for the prediction of cardiovascular disease in type 2 diabetes. Diabetologia 2015 58 1363 1371. doi: 10.1007/s00125-015-3535-6.
17. Blankenberg S, McQueen MJ, Smieja M, Pogue J, Balion C, Lonn E, Rupprecht HJ, Bickel C, Tiret L, Cambien F, Gerstein H, Münzel T, Yusuf S, HOPE Study Investigators Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2006 114 201 208. doi: 10.1161/CIRCULATIONAHA.105.590927.
18. Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, Kaptoge S, Ballantyne C, Cannon CP, Criqui M, Cushman M, Hofman A, Packard C, Thompson SG, Collins R, Danesh J, Lp-PLA(2) Studies Collaboration Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010 375 1536 1544. doi: 10.1016/S0140-6736(10)60319-4.
19. Di Angelantonio E, Gao P, Pennells L, Emerging Risk Factors Collaboration Lipid-related markers and cardiovascular disease prediction. JAMA 2012 307 2499 2506. doi: 10.1001/jama.2012.6571.
20. Interleukin 1 Genetics Consortium Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist: a Mendelian randomisation analysis. Lancet Diabetes Endocrinol 2015 3 243 253. doi: 10.1016/S2213-8587(15)00034-0.
21. Herder C, Donath MY, Interleukin-1 receptor antagonist: friend or foe to the heart? Lancet Diabetes Endocrinol 2015 3 228 229. doi: 10.1016/S2213-8587(15)00035-2.
22. Nicklin MJ, Hughes DE, Barton JL, Ure JM, Duff GW, Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene. J Exp Med 2000 191 303 312
23. Isoda K, Shiigai M, Ishigami N, Matsuki T, Horai R, Nishikawa K, Kusuhara M, Nishida Y, Iwakura Y, Ohsuzu F, Deficiency of interleukin-1 receptor antagonist promotes neointimal formation after injury. Circulation 2003 108 516 518. doi: 10.1161/01.CIR.0000085567.18648.21.
24. Merhi-Soussi F, Kwak BR, Magne D, Chadjichristos C, Berti M, Pelli G, James RW, Mach F, Gabay C, Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice. Cardiovasc Res 2005 66 583 593. doi: 10.1016/j.cardiores.2005.01.008.
25. Elhage R, Maret A, Pieraggi MT, Thiers JC, Arnal JF, Bayard F, Differential effects of interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-streak formation in apolipoprotein E-deficient mice. Circulation 1998 97 242 244
26. Chamberlain J, Evans D, King A, Dewberry R, Dower S, Crossman D, Francis S, Interleukin-1beta and signaling of interleukin-1 in vascular wall and circulating cells modulates the extent of neointima formation in mice. Am J Pathol 2006 168 1396 1403
27. Wensley F, Gao P, Burgess S, C Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC) Association between C reactive protein and coronary heart disease: Mendelian randomisation analysis based on individual participant data. BMJ 2011 342 d548. doi: 10.1136/bmj.d548.
28. Swerdlow DI, Holmes MV, Kuchenbaecker KB, Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium The interleukin-6 receptor as a target for prevention of coronary heart disease: a Mendelian randomisation analysis. Lancet 2012 379 1214 1224. doi: 10.1016/S0140-6736(12)60110-X.
29. Meuwese MC, Stroes ES, Hazen SL, van Miert JN, Kuivenhoven JA, Schaub RG, Wareham NJ, Luben R, Kastelein JJ, Khaw KT, Boekholdt SM, Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol 2007 50 159 165. doi: 10.1016/j.jacc.2007.03.033.
30. Karakas M, Koenig W, Zierer A, Herder C, Rottbauer W, Baumert J, Meisinger C, Thorand B, Myeloperoxidase is associated with incident coronary heart disease independently of traditional risk factors: results from the MONICA/KORA Augsburg study. J Intern Med 2012 271 43 50. doi: 10.1111/j.1365-2796.2011.02397.x.
31. Blankenberg S, Barbaux S, Tiret L, Adhesion molecules and atherosclerosis. Atherosclerosis 2003 170 191 203
32. VanderWeele TJ, Mediation analysis: a practitioner's guide. Annu Rev Public Health 2016 37 17 32. doi: 10.1146/annurev-publhealth-032315-021402.
33. Herder C, Kowall B, Tabak AG, Rathmann W, The potential of novel biomarkers to improve risk prediction of type 2 diabetes. Diabetologia 2014 57 16 29. doi: 10.1007/s00125-013-3061-3.
34. Ioannidis JP, Why most discovered true associations are inflated. Epidemiology 2008 19 640 648. doi: 10.1097/EDE.0b013e31818131e7.